Immunoprecise Soars 30%—Can Bio-Native AI and Nasdaq Compliance Ignite a New Rally?

• IPA surged to $1.93, a 30.69% intraday spike, after regaining Nasdaq compliance and announcing AI-driven drug breakthroughs.
• The stock hit a 52-week high of $1.94, rebounding from a $0.27 low, with turnover spiking to 2.5 million shares.
• Regulatory relief and LENSai platform advancements position IPA as a TechBio disruptor, attracting investor speculation.

This explosive move caps weeks of momentum, with the stock up 222% over six months. The catalyst? A Nasdaq compliance victory and tangible AI advancements now priced into shares, but can the rally sustain beyond technical resistance?

Regulatory Clearance and AI Breakthroughs Drive the Surge
Immunoprecise’s 30.69% intraday surge stems from two critical catalysts: first, its formal notification from Nasdaq confirming compliance with the minimum bid price requirement after 10 consecutive days above $1.00, averting delisting. Second, the company highlighted its LENSai platform’s breakthroughs, including predicting therapeutic interactions for 17 novel antibody-protein complexes with 'near-crystallography precision.' This zero-shot AI capability—critical for drug discovery—has positioned IPA as a leader in bio-native AI, attracting investor confidence. The stock’s rebound from a $0.27 52-week low underscores how regulatory clarity and technological validation can transform a beaten-down biotech’s trajectory.

Target the Breakout with Call Options—LENSai’s Momentum Needs to Hold
Technical indicators signal bullish momentum but warn of overextension:
• 200-day MA: $0.54 (irrelevant due to surge)
• RSI: 64.3 (neutral but trending upward)
• Bollinger Bands: Upper at $1.86, Middle at $1.16—price is testing upper resistance.

Bulls must target a breakout above $1.86 to $2.00. Short-term support holds at $1.50 (day’s low). For aggressive traders, layer calls around resistance:

Top Options Picks:
1. IPA20251121C2 (Call, $2.00 strike, Nov 2025):
• IV: 129.09%, Delta: 0.65, Gamma: 0.241, Theta: -0.002392
• Turnover: 300 contracts (high liquidity)
• Why?: Near-the-money delta (65%) and gamma sensitivity amplify gains if $2.00 is breached. A 5% rise to $2.03 yields a $0.03 payoff, with theta decay minimal.

2. IPA20260220C1.5 (Call, $1.50 strike, Feb 2026):
• IV: 153.27%, Delta: 0.729, Gamma: 0.1398, Theta: -0.001872
• Turnover: 4,063 contracts (exceptional liquidity)
• Why?: Deep ITM delta (73%) ensures immediate premium value. A 5% rise to $2.03 yields a $0.53 payoff, with gamma stability for sustained moves.

Action Alert: Aggressive bulls should buy the Nov $2.00 call if $1.86 resistance holds. A close above $2.00 validates a test of the 2024 high ($2.01). Watch for theta decay risks if momentum stalls below $1.80.

Backtest Immunoprecise Stock Performance
The backtest of IPA's performance after an intraday increase of 31% reveals mixed results. While the 3-Day win rate is high at 40.70%, the 10-Day and 30-Day win rates are lower at 43.76% and 39.61%, respectively. Additionally, the returns over the 3-Day, 10-Day, and 30-Day periods are negative or close to zero, with a maximum return of only 0.58% over 30 days. These findings suggest that following an intraday surge of 31% in IPA may not lead to sustained positive performance in the short to medium term.

Hold the Line at $1.80—Watch for Nasdaq Catalysts and Clinical Data
The rally hinges on sustaining momentum above $1.80, with IPA’s resurgence aligning with its LENSai platform’s validation. Investors must monitor execution risks in its drug discovery pipeline. While sector leader Amgen (AMGN) rose 0.2%, IPA’s AI narrative could carve an independent path. Traders should prioritize call options expiring in late 2025/2026 for maximum leverage. If the stock holds $1.50, the $2.00 barrier becomes the next battleground—failure could invite profit-taking. For now, the bio-native AI story is the engine—watch for partnership news or clinical validations to sustain the ascent. Action Insight: Layer calls below $1.86; exit if $1.50 support collapses.